Publication:
Management of acquired resistance to ALK inhibitors: Repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes

Simple item page
dc.contributor.authorNaiyarat Prasongsooken_US
dc.contributor.authorThanyanan Reungwetwattanaen_US
dc.contributor.otherRamathibodi Hospitalen_US
dc.contributor.otherPhramongkutklao College of Medicineen_US
dc.date.accessioned2022-08-04T08:11:19Z
dc.date.available2022-08-04T08:11:19Z
dc.date.issued2021-03-01en_US
dc.identifier.citationPrecision Cancer Medicine. Vol.4, No.March (2021)en_US
dc.identifier.doi10.21037/pcm-2020-mnsclc-09en_US
dc.identifier.issn26172216en_US
dc.identifier.other2-s2.0-85110627470en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/76252
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85110627470&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.subjectNursingen_US
dc.titleManagement of acquired resistance to ALK inhibitors: Repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomesen_US
dc.typeNoteen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85110627470&origin=inwarden_US

Files

Collections

Scopus 2021